Anthony M Montgomery

US Patent:

7070939, Jul 4, 2006

Filed:

Sep 26, 2001

Appl. No.:

10/130085

Inventors:

Anthony Montgomery - San Diego CA, US
Paul Demarco - Wausau WI, US
Fang Mei - League City TX, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

G01N 33/53
C12Q 1/68
C07K 14/00
C07K 16/00

US Classification:

435 71, 435 6, 530350, 5303871

Abstract:

This invention relates generally to the field of prognosis and diagnosis of vasculopathy and certain tumors. In particular, the invention provides a method for prognosing or diagnosing vasculopathy, neuroectodermal tumor, epithelial tumor, myelomonocytic tumor or lymphoid tumor in a mammal, which method comprises: a) assessing a NCAM L1 protein or a derivative or fragment thereof, or a mRNA encoding said NCAM L1 protein or a derivative or fragment thereof, in a mammal having or suspected of having vasculopathy, neuroectodermal tumor, epithelial tumor, lymphoid tumor or myelomonocytic tumor; b) assessing a NCAM L1 protein or a derivative or fragment thereof, or a mRNA encoding said NCAM L1 protein or a derivative or fragment thereof, in a mammal not having said vasculopathy, neuroectodermal tumor, epithelial tumor, lymphoid tumor or myelomonocytic tumor; c) comparing the presence or quantity of said NCAM L1 protein or mRNA assessed in steps a) and b), whereby said NCAM L1 protein or mRNA assessed in step a) is more than that assessed in step b) indicates the presence of said vasculopathy, neuroectodermal tumor, epithelial tumor, lymphoid tumor or myelomonocytic tumor in said mammal. The method can also be used for monitoring the effectiveness of the treatment of the vasculopathy, neuroectodermal tumor, epithelial tumor, lymphoid tumor or myelomonocytic tumor.

US Patent:

20030040477, Feb 27, 2003

Filed:

Sep 23, 2002

Appl. No.:

10/130087

Inventors:

Anthony Montgomery - San Diego CA, US
Larissa Balaian - San Diego CA, US

International Classification:

A61K038/17
A61K048/00

US Classification:

514/012000, 514/044000

Abstract:

This invention relates generally to the field of immunology or neuroimmunology. In particular, the invention provides a method for reducing or inhibiting T cell activation, which method comprises administering an effective amount of an antagonist of NCAM L1 to a mammal, wherein reduction or inhibition of T cell activation is desirable, thereby reducing or inhibiting T cell activation in said mammal. Combinations and combinatorial methods for modulating T cell activation are further provided. The invention also provides a method for potentiating T cell activation, which method comprises administering an effective amount of a multimerized neural cell adhesion molecule L1 (NCAM L1), or a functional derivative or fragment thereof, or a nucleic acid encoding said L1 or func tional derivative or fragment thereof, or an agent that enhances production and/or costimulatory function of said L1 to a mammal, wherein T cell activation is desirable, thereby potentiating T cell activation in said mammal.

US Patent:

20030228287, Dec 11, 2003

Filed:

Oct 18, 2002

Appl. No.:

10/274529

Inventors:

Gillian Beattie - San Diego CA, US
Alberto Hayek - La Jolla CA, US
Anthony Montgomery - Cardiff CA, US

Assignee:

Regents of the University of California

International Classification:

A61K045/00
C12N005/08

US Classification:

424/093700, 435/366000

Abstract:

The present invention provides a method of culturing cells on a matrix. The present invention includes islet cells cultured in a 3-D configuration in the presence of a fibrin matrix support. Induction of -cell proliferation with HGF/SF is also provided.

US Patent:

20040105857, Jun 3, 2004

Filed:

Mar 21, 2003

Appl. No.:

10/130337

Inventors:

Anthony Montgomery - San Diego CA, US
Peter Brooks - Carmel NY, US
Ralph Reisfeld - La Jolla CA, US

International Classification:

A61K039/395

US Classification:

424/144100

Abstract:

This invention relates generally to the field of angiogenesis. In particular, the invention provides a method for enhancing angiogenesis, which method comprises administering an effective amount of an integrin binding pro-angiogenic agent or an integrin antagonist to a mammal, wherein angiogenesis is desirable, thereby enhancing angiogenesis in said mammal. The invention also provides isolated, angiogenic proteins or peptides or isolated nucleic acids encoding the angiogenic proteins or peptides. Combinations and methods for enhancing angiogenesis are further provided.

US Patent:

20060211038, Sep 21, 2006

Filed:

May 23, 2006

Appl. No.:

11/438821

Inventors:

Anthony Montgomery - Cardiff CA, US
Paul Demarco - Wausau WI, US
Fang Mei - Galveston TX, US

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435006000, 435007230

Abstract:

This invention relates generally to the field of prognosis and diagnosis of vasculopathy and certain tumors. In particular, the invention provides a method for prognosing or diagnosing vasculopathy, neuroectodermal tumor, epithelial tumor, myelomonocytic tumor or lymphoid tumor in a mammal. The invention can also be used for monitoring the effectiveness of the treatment of the vasculopathy, neuroectodermal tumor, epithelial tumor, lymphoid tumor or myelomonocytic tumor.